ArticleCancer drug resistance (Alhambra, Calif.)2023

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers.

Rachel Bayley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.